# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TCAR (Transcarotid Artery Revascularization) is an innovative minimally invasive surgical procedure used to treat carotid arter...
Argus Research analyst Steve Silver upgrades Silk Road Medical (NASDAQ:SILK) from Hold to Buy and announces $24 price target.
Stifel analyst Rick Wise maintains Silk Road Medical (NASDAQ:SILK) with a Buy and raises the price target from $20 to $23.
JP Morgan analyst Robbie Marcus maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from $1...
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as...
Piper Sandler analyst Adam Maeder maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from ...